Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards

Medelis Expands Worldwide CRO Services with New European Division Led by New Managing Director

By Pharmaceutical Processing | October 13, 2008

Medelis, Inc., a contract research organization providing oncology clinical trial design, management and execution, has announced the formation of Medelis Europe and the appointment of Deirdre Tessman, Ph.D., as its Managing Director. Formerly of Tessman Technology Ltd. and ILEX Pharmaceuticals, Dr. Tessman brings more than 30 years of worldwide drug development and regulatory experience to the Medelis organization. She has directed all phases of pharmaceutical development from research through drug approval and marketing with additional expertise in the startup and turnaround of pharmaceutical companies. “We are excited to take this significant step in expanding our geographical coverage and our service offerings to our worldwide clients who wish to bring their drugs to the European community for approval and sale,” said Medelis CEO Bob Bosserman. “Dr. Tessman has a long-term relationship with Medelis, and we’re delighted to make it official,” he continued. “Deirdre has an excellent track record and established reputation for founding and holding senior positions within both CROs and pharmaceutical companies. She is the clear choice to lead our firm’s European office and will be a substantial asset for our U.S. and European clients as well as for Medelis’ continuing evolution as a worldwide leader in oncology drug development.” Her appointment reunites her with former colleagues Dr. Daniel Von Hoff, Dr. Skip Burris, and Dr. Mace Rothenberg, all members of Medelis’ Medical Advisory Board. Medelis Europe delivers complete oncology drug development services from preclinical through phase III. European, U.S. and Asian sponsors looking to bring drugs to the U.S. & European markets can utilize Medelis’ full service offering including EDC for phase I studies, internet-based patient recruitment, and integrated preclinical studies aligning the preclinical, regulatory and clinical teams.

Related Articles Read More >

FDA logo
FDA prevented 317 drug shortages in 2021
Pfizer-BioNTech vaccine vial
Pfizer, BioNTech moving forward on seeking COVID-19 vaccine EUA for youngest children
FDA logo
FDA curtails use of Janssen COVID-19 vaccine over blood clotting concerns
FDA logo
FDA sends warning letters to CBD and delta-8 THC product vendors

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Pharmaceutical Processing news in a minute?

We Deliver!
Pharmaceutical Processing Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Pharmaceutical Processing World
  • Subscribe to Our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards